Related Experiment Video
Updated: Aug 13, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1
1Division of Tumor Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Insights
The Epstein-Barr virus (EBV) BZLF1 gene product, ZEBRA, activates its own promoter through novel binding domains. This ZEBRA binding can bypass the need for the ZII domain, initiating the viral lytic cycle.
Area of Science:
- Virology
- Molecular Biology
- Gene Regulation
Background:
- Epstein-Barr virus (EBV) BZLF1 gene expression triggers the viral lytic cycle in infected lymphocytes.
- The BZLF1 promoter (Zp) has TPA-responsive elements (ZI and ZII), but its activity is lower in EBV-negative cells.
Purpose of the Study:
- To investigate the mechanism by which ZEBRA transactivates its own promoter.
- To identify novel ZEBRA-binding domains and their role in BZLF1 gene regulation.
Main Methods:
- Transactivation assays in EBV-negative and EBV-positive cell lines.
- Identification and characterization of ZEBRA-binding sites on the BZLF1 promoter.
- Analysis of ZEBRA domain homology and binding affinity.
Main Results:
- ZEBRA directly binds to a novel region on Zp, distinct from ZI and ZII.
- This region contains two unique transactivation domains: ZIIIA and ZIIIB.
- ZIIIB exhibits higher binding affinity and no homology to consensus ZEBRA sites.
- Transactivation is independent of the ZII domain, suggesting ZEBRA binding compensates for its absence.
Conclusions:
- ZEBRA autoregulation involves direct binding to unique promoter domains.
- ZEBRA binding can functionally replace the ZII domain, driving BZLF1 transcription.
- This mechanism supports a model where ZEBRA synthesis commits the virus to the lytic cascade.
Abstract:
Expression of the Epstein-Barr virus (EBV) BZLF1 gene in latently infected lymphocytes is sufficient to trigger the viral lytic cycle. As shown in the accompanying report (E. Flemington and S.H. Speck, J. Virol. 64:1217-1226, 1990), the promoter for the BZLF1 gene (Zp) contains two distinct types of elements (ZI and ZII [an AP-1-like domain]) which are responsive to the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), an inducer of the viral lytic cycle. Although Zp can be activated with TPA in an EBV-negative Burkitt's lymphoma cell line (Ramos), its activity is considerably lower than in EBV-positive cell lines which can be induced with TPA. Here we show that the protein product of the BZLF1 gene (ZEBRA) can transactivate its own promoter by a mechanism which involves direct binding to a region distinct from the ZI and ZII element. Moreover, we show that this region is composed of two distinct ZEBRA-binding-transactivation domains. Interestingly, these two domains are not homologous, and while one domain (ZIIIA) is similar to previously described ZEBRA-binding domains, the second (ZIIIB) is a higher-affinity site which bears no detectable homology to the consensus ZEBRA recognition sequence. We also show that transactivation is independent of the otherwise essential ZII domain, suggesting that ZEBRA binding may functionally replace or supercede the need for a functional ZII domain. This observation supports a model for activation of the lytic cycle whereby synthesis of a critical level of ZEBRA signals commitment to BZLF1 transcription and initiation of the lytic cascade.
Related Concept Videos
Leaky Scanning
Rabies

